Advertisement

Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer

  • Wonshik HanEmail author
  • So Young Kang
  • The Korean Breast Cancer Society
Epidemiology

Abstract

Previous studies have reported significantly worse outcomes in younger women with breast cancer. The cut-off for young age differed between studies and it is unclear whether the survival-age relationship is a linear function across age in premenopausal women. We analyzed data on 9,885 breast cancer patients aged ≤50 years who entered the Korean Breast Cancer Society Registration Program between 1992 and 2001. Overall survival data were compared among age groups. The median follow-up duration was 74.4 months. Of all patients, 351 were aged <30 years (Group I), 1,092 were aged 30–34 years (Group II), 2,087 were aged 35–39 years (Group III), and 6,354 were aged 40–50 years (Group IV). In univariate and multivariate analyses, Group I patients showed a worse outcome than Group II patients, and Group II patients showed a worse outcome than Group III patients. Interestingly, the survival rates of Group III and Group IV patients did not differ significantly. This survival trend according to age group was not found in the subgroup of patients with hormone receptor-negative tumors. In patients aged <35 years, the risk of death rose by 5% for every 1-year reduction in age, whereas there was no significant change in death risk with age in patients aged 35–50 years. We show that risk of death from breast cancer increases sharply in women younger than 35 years. This suggests that age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer.

Keywords

Breast cancer Young age Prognosis Survival Premenopausal 

Notes

Acknowledgments

The Korean Breast Cancer Society thanks the following members who participated in this national study: S.H. Ahn, J.W. Bae, Y.T. Bae, J.W. Baek, J.G. Bong, K.H. Cha, E.S. Chang, I.T. Chang, S.S. Chang, J.W. Cho, S.H. Cho, Y.U. Cho, J.W. Choi, K.J. Choi, M.S. Choi, S.I. Choi, S.Y. Choi, G.S. Goo, S.H. Han, W. Han, S.J. Hong, J.Y. Hwang, T.I. Hyun, Y.J. Jegal, M.G. Im, Y.G. Joh, S.Y. Jun, B.W. Jung, J. Jung, J.H. Jung, K.H. Jung, P.J. Jung, S.H. Jung, S.S. Jung, Y.H. Jung, Y.S. Jung, D.H. Kang, H.J. Kang, Y.I. Kang, Y.J. Kang, J.H. Keum, D.Y. Kim, H.J. Kim, J.G. Kim, J.H. Kim, J.S. Kim, J.S. Kim, K.C. Kim, S.C. Kim, S.H. Kim, S.I. Kim, S.J. Kim, S.W. Kim, S.W. Kim, S.Y. Kim, S.Y. Kim, Y.S. Kim, B.K. Ko, S.S. Ko, S.H. Koh, B.H. Koo, J.Y. Koo, B.S. Kwak, C.H. Lee, C.H. Lee, D.H. Lee, D.S. Lee, E.S. Lee, G.S. Lee, H.D. Lee, H.S. Lee, J.C. Lee, J.H. Lee, J.K. Lee, J.S. Lee, J.Y. Lee, K.M. Lee, K.P. Lee, K.S. Lee, K.Y. Lee, M.H. Lee, R.A. Lee, S.C. Lee, S.J. Lee, S.K. Lee, W. Lee, Y.H. Lee, J.W. Leu, C.H. Lim, C.W. Lim, B.I. Moon, Y.S. Nam, S.J. Nam, D.Y. Noh, W.C. Noh, S.J. Oh, S.S. Oh, W.K. Pae, I.W. Paik, N.S. Paik, B.G. Park, B.W. Park, C.H. Park, H.B. Park, H.Y. Park, J.H. Park, K.H. Park, S.J. Park, S.T. Park, S.W. Park, W.C. Park, Y.K. Park, Y.K. Park, H.S. Seo, K.H. Seo, Y.J. Seo, Y.S. Sin, B.H. Son, G.S. Son, B.J. Song, K.H. Song, Y.J. Song, Y.J. Suh, J.M. Won, D.H. Woo, D.H. Yang, J.H. Yang, K.Y. Yoo, S.Y. Yoo, H.S. Yoon, J.H. Yoon, and S.O. Yoon.

References

  1. 1.
    Goldhirsch A, Gelber RD, Yothers G, Gray RJ, Green S, Bryant J, Gelber S, Castiglione-Gertsch M, Coates AS (2001) Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr 30:44–51PubMedGoogle Scholar
  2. 2.
    Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, Han W (2007) Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea—a report from the Korean Breast Cancer Society. J Clin Oncol 25:2360–2368. doi: 10.1200/JCO.2006.10.3754 CrossRefPubMedGoogle Scholar
  3. 3.
    Albain KS, Allred DC, Clark GM (1994) Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr 16:35–42PubMedGoogle Scholar
  4. 4.
    de la Rochefordiere A, Asselain B, Campana F, Scholl SM, Fenton J, Vilcoq JR, Durand JC, Pouillart P, Magdelenat H, Fourquet A (1993) Age as prognostic factor in premenopausal breast carcinoma. Lancet 341:1039–1043. doi: 10.1016/0140-6736(93)92407-K CrossRefPubMedGoogle Scholar
  5. 5.
    Fowble BL, Schultz DJ, Overmoyer B, Solin LJ, Fox K, Jardines L, Orel S, Glick JH (1994) The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys 30:23–33PubMedGoogle Scholar
  6. 6.
    Han W, Kim SW, Park IA, Kang D, Kim SW, Youn YK, Oh SK, Choe KJ, Noh DY (2004) Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer 4:82. doi: 10.1186/1471-2407-4-82 CrossRefPubMedGoogle Scholar
  7. 7.
    Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Schnitt S, Abner A, Recht A, Vicini F, Harris JR (1994) Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 12:888–894PubMedGoogle Scholar
  8. 8.
    Ahn SH, Yoo KY (2006) Chronological changes of clinical characteristics in 31, 115 new breast cancer patients among Koreans during 1996–2004. Breast Cancer Res Treat 99:209–214. doi: 10.1007/s10549-006-9188-x CrossRefPubMedGoogle Scholar
  9. 9.
    Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thurlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortes-Funes H, Simoncini E, Werner ID, Coates AS, Goldhirsch A (2000) Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 355:1869–1874. doi: 10.1016/S0140-6736(00)02292-3 CrossRefPubMedGoogle Scholar
  10. 10.
    Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Orlando L, Ghisini R, Viale G, Pruneri G, Veronesi P, Luini A, Intra M, Cardillo A, Torrisi R, Rocca A, Goldhirsch A (2006) Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol 17:1497–1503. doi: 10.1093/annonc/mdl145 CrossRefPubMedGoogle Scholar
  11. 11.
    Walshe JM, Denduluri N, Swain SM (2006) Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 24:5769–5779. doi: 10.1200/JCO.2006.07.2793 CrossRefPubMedGoogle Scholar
  12. 12.
    International Breast Cancer Study Group (1996) Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 14:1885–1894Google Scholar
  13. 13.
    Aebi S (2005) Special issues related to the adjuvant therapy in very young women. Breast 14:594–599. doi: 10.1016/j.breast.2005.08.011 CrossRefPubMedGoogle Scholar
  14. 14.
    Choi DH, Kim S, Rimm DL, Carter D, Haffty BG (2005) Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray. Cancer J 11:404–411. doi: 10.1097/00130404-200509000-00008 CrossRefPubMedGoogle Scholar
  15. 15.
    Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G, Luini A, Veronesi P, Intra M, Orecchia R, Catalano G, Galimberti V, Nole F, Martinelli G, Goldhirsch A (2002) Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 13:273–279. doi: 10.1093/annonc/mdf039 CrossRefPubMedGoogle Scholar
  16. 16.
    Dai H, van’t Veer L, Lamb J, He YD, Mao M, Fine BM, Bernards R, van de Vijver M, Deutsch P, Sachs A, Stoughton R, Friend S (2005) A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 65:4059–4066. doi: 10.1158/0008-5472.CAN-04-3953 CrossRefPubMedGoogle Scholar
  17. 17.
    Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826. doi: 10.1056/NEJMoa041588 CrossRefPubMedGoogle Scholar
  18. 18.
    Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324–3330. doi: 10.1200/JCO.2007.14.2471 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Wonshik Han
    • 1
    • 2
    Email author
  • So Young Kang
    • 1
  • The Korean Breast Cancer Society
  1. 1.Cancer Research InstituteSeoul National University College of MedicineSeoulKorea
  2. 2.Department of SurgerySeoul National University College of MedicineSeoulKorea

Personalised recommendations